Disclaimer

"Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Declaratory judgment of invalidity and noninfringement of U.S. Patent Nos. 7,858,122 ("Extended Release Formulation of Levetiracetam," issued December 29, 2010) and 7,863,316 (same title, issued January 4, 2011) based on Par's filing of an ANDA to manufacture a generic version of UCB's Keppra XR® (levetiracetam, used to treat epilepsy). View the complaint here.

Infringement of U.S. Patent No. 7,718,634 ("Method of Treatment Using Bisphosphonic Acid," issued May 18, 2010), licensed to Warner Chilcott, following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Warner Chilcott's Once-a-Month Actonel® (risedronate sodium, used to treat and prevent postmenopausal osteoporosis). View the complaint here.

The complaints in these cases are substantially identical. Infringement of U.S. Patent Nos. 7,101,574 ("Pharmaceutical Composition Containing Fenofibrate and the Preparation Method," issued September 5, 2006) and 7,863,331 ("Pharmaceutical Composition Containing Fenofibrate and Method for the Preparation Thereof," issued January 4, 2011) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Lupin's Antara® (fenofibrate, used to treat hypercholesterolemia and hypertriglyceridemia). View the Delaware Lupin complaint here.

Infringement of U.S. Patent Nos. 5,843,946 ("α- and β-Amino Acid Hydroxyethylamino Sulfonamides Useful as Retroviral Protease Inhibitors," issued December 1, 1998) and 7,700,645 ("Pseudopolymorphic Forms of a HIV Protease Inhibitor," issued April 20, 2010) following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Tibotec's Prezista® (darunavir, used to treat human immunodeficiency virus (HIV-1) infection). View the complaint here.

Nycomed US Inc. v. Glycobiosciences Inc.2:11-cv-01539; filed March 11, 2011 in the District Court of New Jersey

Declaratory judgment of noninfringement of U.S. Patent No. 5,897,880 ("Topical Drug Preparations," issued April 27, 1999) based on Nycomed's manufacture and sale of Solaraze® (diclofenac sodium, used to actinic keratosis). View the complaint here.